Product Information
QELBREE ER 150 MG CAPSULE is a brand product labeled by Supernus Pharmaceuticals Inc., priced at $12.7426 per EA under NDC 17772013230. Its NADAC has been published 227 times since Feb 23, 2022.
Strength
150 mg/1
Manufacturer
Supernus Pharmaceuticals Inc.NDC
17772013230
Classification
Brand
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Last Updated
6/17/2026
Active Ingredients
VILOXAZINE HYDROCHLORIDEApproval Type
New Drug (NDA)
FDA Application
NDA211964On Market Since
4/2/2021
Pharmacological Classes
Price Statistics
The NADAC for QELBREE ER 150 MG CAPSULE has been published 227 times since Feb 23, 2022, and over the history we have for it it has risen 26.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $12.7426 per EA |
|---|---|
| All-time high | $12.7546 (Jun 10, 2026) |
| All-time low | $10.1146 (Feb 23, 2022) |
| 52-week high | $12.7546 |
| 52-week low | $12.0140 |
| Median price | $11.3595 |
| Average price | $11.2776 |
| Largest weekly change | +6.0% (Jan 3, 2024) |
| Weeks tracked | 227 |
| Tracking since | Feb 23, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the viloxazine hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Frequently asked questions
What is the NADAC price of QELBREE ER 150 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for QELBREE ER 150 MG CAPSULE, manufactured by Supernus Pharmaceuticals Inc., is $12.7426 per EA (NDC 17772013230), effective Jun 24, 2026.
How has the price of QELBREE ER 150 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for QELBREE ER 150 MG CAPSULE has risen 26.0%. It has been tracked across 227 weekly CMS publications since Feb 23, 2022.
What are the highest and lowest recorded NADAC prices for QELBREE ER 150 MG CAPSULE?
Since Feb 23, 2022, the NADAC for QELBREE ER 150 MG CAPSULE has ranged from a low of $10.1146 (Feb 23, 2022) to a high of $12.7546 (Jun 10, 2026), with a median of $11.3595 per EA.
Are there cheaper alternatives to QELBREE ER 150 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient, strength, and dosage form of QELBREE ER 150 MG CAPSULE, so no direct lower-cost alternative is listed.
Who manufactures QELBREE ER 150 MG CAPSULE?
QELBREE ER 150 MG CAPSULE (NDC 17772013230) is labeled by Supernus Pharmaceuticals Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification